Drug Pipeline News

During clinical validation done by the company, Unity Confirm demonstrated 100% concordance with known fetal outcomes and invasive diagnostic results in 16 samples.

These are the top 5 headlines you might have missed in April 2026 from Contemporary OB/GYN.

The expanded label to include use during pregnancy complicated by type 1 diabetes mellitus is based on data from the CIRCUIT trial.

Utepreva LLC has launched a proprietary, FDA-cleared endometrial sampler that combines suction, disruption, and absorption to improve tissue yield in 20-second office procedures.

The letter from the federal agency allows further phase 2 development for refisolone under an investigational new drug application.

Ramu Perni highlights how the "one tube" workflow streamlines obstetric practices by enabling add-on RBC and platelet antigen tests.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

The FDA cleared the Onclarity HPV Self-Collection Kit, allowing patients to collect samples at home for processing via the FDA-cleared BD Onclarity HPV Assay and BD COR System.

The Ringza slow-release vaginal ring has launched in Canada and is designed to be re-used for up to 1 year.

Researchers developed a porous membrane organ-on-a-chip that replicates the human cervix to study how the microbiome and immune system interact with chlamydia and gonorrhea.

Take a look back at some of the top FDA-related news items—from de Novo clearances to advancing trials—that Contemporary OB/GYN covered in the first quarter of 2026.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

From FDA regulatory updates for products related to women's health, to a preview of upcoming annual meetings and conferences, we keep you updated on what's to come in Q2 of 2026.

Livi is a single-use, soft polyurethane foam device cleared by the FDA to absorb semen and vaginal discharge within approximately 60 seconds.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

ENDO-205 is EndoCyclic Therapeutics' lead program and consists of a first-in-class, non-hormonal targeted epeptide therapeutic for endometriosis, according to the company.

Among 2029 women in Scandinavian countries who were followed up for 14 years, vaccine effectiveness was 100%.

The FDA has cleared a cloud-based AI tool that predicts delivery dates solely from ultrasound images.

A prospective observational study found that age did not independently affect bone mineral density response to romosozumab in postmenopausal women.

The label changes to 6 menopausal HRTs "clarify risk considerations for these drugs," according to a statement from the FDA.

If allowed by prescribers, patients can complete pregnancy tests outside of a medical setting, but must complete pre-treatment pregnancy tests in a medical setting, according to the FDA.

Take a quick look at everything you may have missed in January, from our latest video interviews to new clinical trial data to a FAQ on cervical cancer.

New FDA guidance and AACR-bound data highlight Aviva Bio’s progress in developing a differentiated testosterone therapy aimed at reducing breast cancer risk in women.